PBA
ALXO icon

Paradigm Biocapital Advisors’s ALX Oncology ALXO Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,575,605
Closed -$9.5M – 35
2024
Q2 		$9.5M Buy
+1,575,605
New +$19.4M 0.36% 31

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paradigm Biocapital Advisors's ALXO Position: Q3 2024 in Review

Paradigm Biocapital Advisors sold out of ALX Oncology (ALXO) in Q3 2024, closing a stake of 1,575,605 shares — an estimated $9.5M sold.

Paradigm Biocapital Advisors first reported a position in ALXO in Q2 2024 and held it in 1 quarter. The position peaked at $9.5M in Q2 2024. 92 funds tracked by Wall St. Rank hold ALXO as of Q3 2024.

  • Paradigm Biocapital Advisors reported no remaining ALX Oncology position as of Q3 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,575,605 ALX Oncology shares in Q3 2024, an estimated $9.5M.
  • Paradigm Biocapital Advisors first reported a position in ALX Oncology in Q2 2024 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's ALX Oncology position peaked at $9.5M in Q2 2024.
  • 92 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.